Dr. Saez is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
6957 W Plano Pkwy
Ste 2000A
Plano, TX 75093Phone+1 214-483-6933Fax+1 214-483-6648
Education & Training
University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of MedicineFellowship, Hematology and Medical Oncology, 1985 - 1989
University of Texas Southwestern Medical CenterResidency, Internal Medicine, 1983 - 1985- University of Texas Southwestern Medical CenterInternship, Internal Medicine, 1982 - 1983
University of Puerto Rico School of MedicineClass of 1982
Certifications & Licensure
TX State Medical License 1983 - 2026
FL State Medical License 1997 - 2025
OK State Medical License 1989 - 2005- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
Clinical Trials
- MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I Start of enrollment: 2011 Oct 01
- PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score Start of enrollment: 2012 May 01
Publications & Presentations
PubMed
- 36 citationsChemoradiotherapeutic Magnetic Nanoparticles for Targeted Treatment of Nonsmall Cell Lung Cancer.Imalka Munaweera, Yi Shi, Bhuvaneswari Koneru, Ruben Saez, Ali E. Aliev
Molecular Pharmaceutics. 2015-09-14 - 63 citationsPhase II trial of irinotecan, carboplatin, and bevacizumab in the treatment of patients with extensive-stage small-cell lung cancer.David R. Spigel, F. Anthony Greco, John D. Zubkus, Patrick B. Murphy, Ruben A. Saez
Journal of Thoracic Oncology. 2009-12-01 - 32 citationsCombination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocyt...John D. Hainsworth, Elizabeth R. Vazquez, David R. Spigel, Eric L. Raefsky, James D. Bearden
Cancer. 2008-03-15
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
